CompanySBFM SBFMWNasdaqFort Lauderdale, FL

Sunshine Biopharma Inc.

Sunshine Biopharma develops mRNA and protease inhibitor therapeutics for oncology and viral infections, including K1.1 mRNA for liver cancer and SBFM-PL4 for SARS coronavirus.

Stories only

SEC EDGAR ClinicalTrials.gov sunshinebiopharma.com

8-KSep 16Latest SEC filing, period to Sep 15

Aug 28Latest story

August 2026

Sunshine Biopharma director Andrew Keller to leave board at next annual meeting

Aug 28PeopleSunshine Biopharma Inc.

Sunshine Biopharma files S-1 for shares tied to Series B warrants

Aug 28FinancingSunshine Biopharma Inc.

July 2026

Sunshine Biopharma files $4 million at-the-market stock offering with Aegis Capital

Jul 20FinancingSunshine Biopharma Inc.

Sunshine Biopharma sets up $4 million at-the-market stock sale facility with Aegis Capital

Jul 20PartnershipSunshine Biopharma Inc.

Sunshine Biopharma settles dispute with former Nora Pharma president

Jul 10PartnershipSunshine Biopharma Inc.